Internal Quality Unit Helps UK’s Klinge Chemicals Resolve FDA Warning Letter
This article was originally published in The Pink Sheet Daily
The company did not find it necessary to hire outside consultants to resolve water quality problems FDA cited in a 2010 warning letter.
You may also be interested in...
When an FDA inspection of a drug manufacturing plant turns up potential violations that are noted on the official Form 483 report, the company should respond in complete detail within 15 days or risk having its response officially disregarded.
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.